Juvenile idiopathic arthritis (JIA) and pediatric joint disorders
Jaime Guzman, MD, MSc
University of British Columbia and BC Children's Hospital
Vancouver, British Columbia, Canada
Disclosure information not submitted.
Nicolino Ruperto, n/a
IRCCS Giannina Gaslini
Genova, Genoa, Italy
Disclosure(s): AbbVie/Abbott: Consultant (Terminated, March 20, 2023); AclarisTx: Consultant (Ongoing); Amgen: Consultant (Ongoing); AstraZeneca(Medimmune: Consultant (Ongoing); Aurinia: Consultant (Ongoing); Boehringer Ingelheim: Consultant (Ongoing); Bristol Myers and Squibb: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); Galapagos/AlfaSigma: Consultant (Ongoing); Guidepoint: Consultant (Ongoing); Idorsia: Consultant (Ongoing); Janssen: Consultant (Ongoing); Novartis: Consultant (Ongoing); Pfizer: Consultant (Ongoing); Roche Genentech: Consultant (Ongoing); Takeda: Consultant (Ongoing)
The outcomes of juvenile idiopathic arthritis (JIA) vary greatly across the world. There may be three main reasons for this: genetic factors, referral biases to pediatric rheumatology, and differential access to JIA treatments. This session will explore these three possible causes using data from large cohorts to outline variations in JIA disease presentation, treatments used, and outcomes attained in different regions. Attendees can then reflect on where the true lies and what needs to be done to help improve JIA outcomes across the world.
Speaker: Alessandro Consolaro, n/a – IRCCS Istituto Giannina Gaslini
Speaker: Angela Migowa, MBChB,MMed – AGA KHAN UNIVERSITY
Speaker: Daniel Horton, MD, MS – Rutgers Robert Wood Johnson Medical School